First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.

被引：7

作者：

Bendell, Johanna ^{[1
]}

Blumenschein, George ^{[2
]}

Zinner, Ralph ^{[2
]}

Hong, David ^{[2
]}

Jones, Suzanne ^{[1
]}

Infante, Jeffrey ^{[1
]}

Burris, Howard ^{[1
]}

Rajagopalan, Prabhu ^{[3
]}

Kornacker, Martin ^{[4
]}

Henderson, David ^{[4
]}

Kelly, Andrea ^{[3
]}

Hassan, Raffit ^{[5
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Bayer HealthCare Pharmaceut, Montville, NJ USA

[4] Bayer Pharma AG, Berlin, Germany

[5] NCI, NIH, Bethesda, MD 20892 USA

来源：

关键词：

D O I：

10.1158/1538-7445.AM2013-LB-291

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB291

引用

页数：1